AJP - Heart Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 290: H1370-H1377, 2006. First published October 21, 2005; doi:10.1152/ajpheart.00523.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/4/H1370    most recent
00523.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segers, V. F. M.
Right arrow Articles by De Keulenaer, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segers, V. F. M.
Right arrow Articles by De Keulenaer, G. W.

CALL FOR PAPERS
Regulation and Function of Stem Cells in the Cardiovascular System

Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms

Vincent F. M. Segers,1 Ivan Van Riet,2 Luc J. Andries,3 Katrien Lemmens,1 Marc J. Demolder,1 Ann J. M. L. De Becker,2 Mark M. Kockx,3 and Gilles W. De Keulenaer1

1Laboratory of Physiology, University of Antwerp, Antwerp, Belgium; 2Department of Haematology-Stem Cell Laboratory, Free University Brussels, Brussels, Belgium; and 3HistoGeneX, Edegem, Belgium

Submitted 19 May 2005 ; accepted in final form 17 October 2005


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Circulating stem cells home within the myocardium, probably as the first step of a tissue regeneration process. This step requires adhesion to cardiac microvascular endothelium (CMVE). In this study, we studied mechanisms of adhesion between CMVE and mesenchymal stem cells (MSCs). Adhesion was studied in vitro and in vivo. Isolated 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-labeled rat MSCs were allowed to adhere to cultured CMVE in static and dynamic conditions. Either CMVE or MSCs were pretreated with cytokines [IL-1beta, IL-3, IL-6, stem cell factor, stromal cell-derived factor-1, or TNF-{alpha}, 10 ng/ml]. Control or TNF-{alpha}-treated MSCs were injected intracavitarily in rat hearts in vivo. In baseline in vitro conditions, the number of MSCs that adhered to CMVE was highly dependent on the flow rate of the superfusing medium but remained significant at venous and capillary shear stress amplitudes. Activation of both CMVE and MSCs with TNF-{alpha} or IL-1beta before adhesion concentration dependently increased adhesion of MSCs at each studied level of shear stress. Consistently, in vivo, activation of MSCs with TNF-{alpha} before injection significantly enhanced cardiac homing of MSCs. TNF-{alpha}-induced adhesion could be completely blocked by pretreating either CMVE or MSCs with anti-VCAM-1 monoclonal antibodies but not by anti-ICAM-1 antibodies. Adhesion of circulating MSCs in the heart appears to be an endothelium-dependent process and is sensitive to modulation by activators of both MSCs and endothelium. Inflammation and the expression of VCAM-1 but not ICAM-1 on both cell types have a regulatory effect on MSC homing in the heart.

cardiac regeneration; heart failure


ADULT STEM CELLS have been considered to be restricted in their differentiative and regenerative potential to the tissues in which they reside. Recently, this traditional view of adult stem cell function has been challenged (4). For example, it has been shown that mesenchymal stem cells (MSCs), usually residing in the adult bone marrow together with hematopoietic stem cells, were highly plastic and may differentiate into cartilage, bone, fat, muscle (23), and cardiomyocytes (18, 29). These findings suggest that circulation and homing of these cells in various organs is part of a previously unrecognized regeneration process. Hence, the physiological relevance of MSCs residing in cardiac tissue was initially ascribed to the replacement of damaged cardiomyocytes. Recent reports indicate, however, that stimulation of neovascularization and paracrine effects of MSCs may be of equal importance (24, 28).

MSCs have been detected in circulating blood of mammalian species (14) and found to migrate into different organs, such as heart, liver, spleen, or lungs (3, 22). The process of homing of circulating stem cells in the bone marrow has been studied in detail. This process is clinically highly relevant as it is crucial for therapeutic transplantation of hematopoietic stem cells. In the bone marrow, homing is a multistep process that shares components with the extravasation of leukocytes at inflammatory sites with a significant role for interactions between stem cells and bone marrow endothelium (26). Only few studies, however, have examined interaction of stem cells with endothelial cells in the vasculature outside the bone marrow (12, 21, 25).

Cardiac endothelial cells in the endocardium and myocardial capillaries play a modulatory role on cardiac development and pump performance. At these locations, cardiac endothelial cells directly interact with surrounding cardiomyocytes through paracrine and nonparacrine mechanisms (5, 8). From this point of view, the heart functions as a pluricellular, multifunctional organ, in which the endothelium is a crucial functional component in cardiac metabolism, growth, contractile performance, and rhythmicity (5). In the present study we hypothesize that besides these established functions, cardiac endothelium may also have a modulatory role in cardiac regeneration. More specifically, we postulate that cardiac microvascular endothelium (CMVE) may play a role in homing and migration of circulating stem cells to myocardium and, as such, may act as a modulator of cardiac cellular homeostasis. Hence, we examined adhesion of MSCs to cardiac endothelium and determined whether a selected set of cytokines affected this process.

The inflammatory cytokines TNF-{alpha} and IL-1beta were selected because they increase adhesion molecule expression in endothelial cells (20) and are released after myocardial damage (7). IL-3, IL-6, and stem cell factor (SCF) were tested because these cytokines play a role in homing of hematopoietic stem cells (31). IL-6 was selected because it is markedly upregulated in cardiac failure and has a protective role in the progression of pump failure (1), whereas stromal cell-derived factor-1 (SDF-1) was tested because it has been proposed to participate in homing of stem cells to the heart (10).


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cell Cultures

Endothelial cell cultures. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publications No. 85-23, Revised 1996). All animal protocols were approved by the local ethical committee for animal research (University of Antwerp). CMVE and aortic endothelial cells (AE) were isolated and cultured from adult Sprague-Dawley rats as previously described (11).

MSC cultures. Femur and tibia of Sprague-Dawley rats were excised, and connective tissue was removed (3). Bone marrow cavity was flushed with complete culture medium. Marrow plug suspension was dispersed by passing it through subsequent pipettes of decreasing sizes. Once a homogeneous cell suspension was achieved, mononuclear cells were isolated using density gradient centrifugation (Ficoll-Paque, Amersham Biosciences), mononuclear cells were plated at 8 x 106 cells/cm2, and nonadherent cells were removed after 4 h. The mesenchymal population was isolated based on plastic adherence and was cultured in RPMI-1640 with 10% FCS of a selected batch (GIBCO, Invitrogen). At 90% confluence, the cells were trypsinized (0.25% trypsin-EDTA) and passaged at 1:9 ratios. For adhesion experiments, MSCs at passage 4 and later were used.

Adhesion Assays

Adhesion assays were performed using eight-well glass chamber slides (Falcon CultureSlide) on which 2 x 104 CMVE (passages 2–4) were plated, reaching confluence after 3 days. Unless otherwise stated, all experiments were performed with 8 x 103 MSCs labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI; Molecular Probes) and diluted in 0.15 ml RPMI. After incubation at 37°C (1–16 h), wells were gently washed three times with PBS, and adherent cells were counted in 10 fields (250-fold magnification) per well using fluorescence microscopy (Zeiss). The number of adhering cells was normalized to the total number of added cells. In some experiments, CMVE or MSCs were pretreated for adhesion studies with one of the following substances: TNF-{alpha} (0.1–100 ng/ml), IL-1beta (0.1–100 ng/ml), SCF (10 ng/ml), SDF-1 (10 ng/ml), IL-3 (10 ng/ml), IL-6 (10 ng/ml) (Sigma), anti-VCAM-1 antibody (mouse monoclonal anti-rat, clone 5F10, 10 µg/ml, Eurogentec), or anti-ICAM-1 antibody (mouse monoclonal anti-rat, clone 1A29, 10 µg/ml, Research Diagnostics).

Flow Chamber Adhesion Assays

Flow adhesion experiments were performed in a parallel plate flow microchamber with a slit height of 0.25 mm and slit width of 10 mm. CMVE (passages 2–4) were cultured to confluence on poly-L-lysine- and collagen (Sigma)-coated glass microscope slides. These slides were attached to the bottom of the flow chamber 15 min before flow experiments. Perfusion of flow chambers at different levels of shear stress (0.5, 1, 2, 5, or 10 dyn/cm2) was conducted for 2 h with circulating RPMI medium (37°C) containing 200 MSCs/µl. MSCs were labeled with DiI as described earlier. Thereafter, chambers were perfused for 15 min with cell-free medium at 2 dyn/cm2 to remove loose cells. Adherent MSCs were counted with fluorescence microscopy (5 fields at x100 magnification). In some experiments either MSCs or CMVE was pretreated with TNF-{alpha} (10 ng/ml) for 24 h before adhesion assays. Experiments were repeated at least three times.

Rat Model of In Vivo Adhesion of MSCs

Sixteen adult Sprague-Dawley rats (150 g) were randomized into two groups. One group received intraventricular injection of control MSCs, and the other group received MSCs pretreated with TNF-{alpha} (10 ng/ml, 24 h). For MSC injection, rats were anesthetized with fentanyl (0.05 mg/kg im, Janssen-Cilag), diazepam (5 mg/kg im, Roche), and haloperidol (3 mg/kg im, Janssen-Cilag) and subsequently intubated endotracheally. A left lateral thoracotomy and pericardiotomy were performed, exposing the heart and ascending aorta. In a separate group of six rats, a procedure of myocardial ischemia (30 min)-reperfusion injury was induced by temporary left anterior descending coronary artery ligation. Twenty-four hours later, MSCs were injected, following the same procedure as described below.

MSCs labeled with DiI were prepared for infusion by detaching the cells from the culture plates by 10-min incubation with 0.25% trypsin-EDTA. Cell solution was passed through a 40-µm nylon cell strainer (BD Falcon) to remove cell aggregates and centrifuged (1,000 rpm, 7 min); 1.5 x 106 MSCs were diluted in 0.5 ml PBS and were injected into the left ventricular cavity while the ascending aorta was clamped (15 s) to mimic intracoronary injection. The rats were monitored for 2 h postoperatively and received an additional subcutaneous dose of fentanyl (0.03 mg/kg) before returning to their cages. All rats survived the procedure.

Twenty-four hours after injection, hearts were removed, fixed with 4% paraformaldehyde solution through Langendorff perfusion, and left overnight in a 20% sucrose solution. Three cryosections per heart, separated by at least 10 sections, were made in the midventricular region. Three digital images were made with fluorescence microscopy (low magnification, x40), and an observer unaware of the experimental protocol (control vs. TNF-{alpha}-treated MSCs) counted cells in the sections.

Immunofluorescent Staining

Endothelial cells in cryosections (20 µm) were stained with mouse monoclonal anti-rat endothelial cell antigen (anti-RECA; Serotec) antibody and secondary goat anti-mouse coupled to Alexa Fluor 488 (Molecular Probes) antibody. Cryosections (10–20 µm) of infarcted hearts were stained with phalloidin-Alexa Fluor 488 for F-actin to discriminate normal from damaged cardiomyocytes. Cellular nuclei were counterstained with Hoechst. Images were captured with fluorescence microscopy (Zeiss Axioplan 2, Apotome, Axiocam HRm and Axiovision software). ZVI-images were exported as TIFF or JPG files and further processed in Adobe Photoshop.

RT-PCR

mRNA was isolated in TRIzol Reagent (Invitrogen, Life Technologies) following instructions of the manufacturer. RT-PCR was performed with One-Step RT-PCR System (Life Technologies) in 25-µl reaction volume containing 0.5 µl total RNA (10–100 ng), 12.5 µl reaction mix, 400 nM of both primers, and 0.5 µl Superscript II/Taq mix (Life Technologies). After initial incubation of 30 min at 50°C and 2 min at 94°C, 35 PCR cycles were performed, which consisted of 15-s denaturation at 94°C, 30-s annealing at 55°C, and a 1-min extension at 72°C, with a final extension step of 7 min. Primers used are listed in Table 1.


View this table:
[in this window]
[in a new window]
 
Table 1. PCR primers and probes used in the study

 
Flow Cytometry

Cells were harvested using trypsin/EDTA and incubated 10 min with 10 µg/ml FITC-labeled monoclonal antibody in RPMI per 5 x 104 cells at room temperature in the dark. Anti-rat CD34 (mouse monoclonal anti-rat, clone ICO115, Santa Cruz Biotechnology), anti-rat CD45 (leukocyte common antigen, mouse monoclonal anti-rat, clone OX-1, BD Biosciences Pharmingen), anti-rat CD29 (beta1-integrin, Armenian hamster monoclonal anti-rat, clone Ha2/5, BD Biosciences Pharmingen), and anti-rat CD90 (Thy-1, mouse monoclonal anti-rat, clone OX-7, Abcam) were used. Cells were washed twice with PBS-0.1% BSA. Labeled samples were examined with a Coulter Epics XL-MCL flow cytometer (Coulter). At least 10,000 events were analyzed and compared with isotype controls.

Real-Time PCR

Real-time PCR was performed for VCAM-1 and very late antigen-4 (VLA-4, {alpha}4-chain). CMVE and MSCs were cultured on six-well plates (Falcon, VWR international) for 2 days and serum starved for the last 7 h, during which some of the products used in adhesion assays were added. mRNA was isolated in TRIzol Reagent (Invitrogen). Real-Time PCR was performed with TaqMan One-Step RT-PCR System (Applied Biosystems) in 25 µl reaction volume containing 1 µl total RNA (10–100 ng), 12.5 µl One-Step RT-PCR Master Mix, 100–800 nM of both primers, 200 nM TaqMan Probe, and 0.5 µl RNase inhibitor. TaqMan probes were labeled with FAM reporter dye and TAMRA quencher dye. After initial incubation of 30 min at 48°C and 10 min at 95°C, 45 PCR cycles were performed, which consisted of 15-s denaturation at 95°C and 60-s annealing and extension at 60°C. Primers and TaqMan probes used are listed in Table 1. Expression of VCAM-1 and VLA-4 mRNA was normalized to expression of GAPDH mRNA.

Statistical Analysis

Adhesion assays were performed in duplicates. Mean values were compared with one-way ANOVA with Bonferroni correction for multiple comparisons. Real-time PCR experiments were performed four times, and differences in threshold cycle values between VCAM-1 or VLA-4 and GAPDH were compared with one-way ANOVA with Bonferroni correction for multiple comparisons. Statistical analysis was performed with SPSS software (SPSS).


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Validation of MSC Culture

MSCs presented as a homogeneous fibroblastoid cell population. Expression of stem cell markers assessed with RT-PCR showed that after passage 2 these cells were completely negative for hematopoietic cell markers (CD34 and CD45) and positive for CD90, CD105, CD166 (ALCAM), which are markers of MSCs (RT-PCR, Fig. 1A) (22). Flow cytometric analysis of passage 4 cells confirmed that cells were negative for CD34 and CD45 and that cells were positive for CD29 (beta1-integrin) and CD90 (Thy-1) (Fig. 1B). Only cells at passage 4 and further passages were used for adhesion experiments.


Figure 1
View larger version (79K):
[in this window]
[in a new window]
 
Fig. 1. Molecular characterization of mesenchymal stem cells (MSCs). A: RT-PCR of passage 2. Cells were negative for CD34 (hematopoietic stem cell marker) and positive for CD90, CD105, and CD166 (MSC markers). B: passage 4 was analyzed with flow cytometry by using antibodies against CD34, CD45, CD29, and CD90. Antibodies are represented by solid black lines; gray lines represent isotype controls. Cells were negative for CD34 and CD45 (leukocyte marker) and positive for CD29 and CD90 (MSC markers).

 
Adhesion of MSCs to CMVE

In static conditions, adhesion of MSCs to CMVE was dependent on the period that cells were allowed to interact, reaching a maximum after 4 h of incubation (n = 4; 1 h, 8 ± 3%; 2 h, 17 ± 1%; 4 h, 25 ± 3%). Percentage of MSCs that adhered to CMVE was fairly independent of the number of MSCs incubated, at least between 4,000 and 16,000 cells added per well (not shown). When adhesion experiments were performed in dynamic conditions in which medium containing MSCs was superfused during 2 h (200 MSCs/µl), increasing flow velocity (shear stress from 0.5 to 5 dyn/cm2) exponentially decreased adhesion of MSCs to CMVE from 2,063 ± 360 to 113 ± 24 cells/cm2 (see Fig. 3). At higher levels of shear stress, adhesion remained unchanged between 5 and 10 dyn/cm2 (75 ± 17 cells/cm2).


Figure 3
View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3. Effect of shear stress on adhesion. A flow chamber with a confluent CMVE monolayer on the bottom was perfused for 2 h with medium containing 200 MSCs/µl. Adhesion of MSCs to CMVE decreased with increasing levels of shear stress. MSCs ({blacksquare}) or CMVE ({blacktriangleup}) were pretreated with TNF-{alpha} for 24 h, resulting in a significant upward shift of both curves. Values are means ± SE.

 
Influence of Cytokines on Adhesion of MSCs to CMVE

A first screening experiment in static conditions, in which CMVE was treated with six different cytokines (10 ng/ml, 24 h), showed that only pretreatment of CMVE with TNF-{alpha} or IL-1beta increased adhesion of MSCs (Fig. 2A). Pretreating CMVE with IL-3, IL-6, SCF, or SDF-1 did not affect adhesion efficiencies (n = 6, Fig. 2A). The effect of TNF-{alpha} or IL-1beta was confirmed in dynamic conditions (Fig. 3) and appeared to be concentration dependent. At 100 ng/ml TNF-{alpha}, for example, the percentage of MSCs that adhered to CMVE increased from 26 ± 3% to 52 ± 5% (n = 6, P < 0.001, Fig. 2B). Similar results were observed when CMVE was pretreated with IL-1beta (at 100 ng/ml, the percentage of MSCs adhering to CMVE increased from 23 ± 1% to 63 ± 6%, n = 6, P = 0.002, Fig. 2C). When MSCs, instead of CMVE, were pretreated with TNF-{alpha} during 24 h before incubation with CMVE, adhesion of MSCs to CMVE also increased (n = 6, increase from 28 ± 2% to 72 ± 2%, Fig. 2D). When both MSCs and CMVE were pretreated, adhesion was still a little greater, but effects were not additive. In flow-chamber experiments, pretreatment of CMVE or MSCs with TNF-{alpha} (10 ng/ml, 24 h) enhanced adhesion of MSC at every studied level of shear stress (Fig. 3, values of TNF-{alpha}-treated groups are significantly different from control at all shear stress levels, P < 0.05, n = 3). MSCs also adhered to confluent cultures of AE, and the degree of adhesion did not differ significantly from adhesion to CMVE, either in basal conditions (24 ± 2% for CMVE, 18 ± 2% for AE, n = 6, P = 1) or after stimulation with TNF-{alpha} (48 ± 4% for CMVE, 49 ± 6% for AE, P = 1, Fig. 2E).


Figure 2
View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2. Adhesion assays. A: adhesion (y-axis: % of 8,000 initial plated MSCs) after pretreatment (24 h) of cardiac microvascular endothelium (CMVE) with different cytokines (10 ng/ml). SCF, stem cell factor; SDF, stromal cell-derived factor; Ctrl, control. B: concentration-dependent increase of MSC adhesion to CMVE after pretreatment of CMVE with TNF-{alpha} 24 h before adhesion assay. C: concentration-dependent increase of MSC adhesion after pretreatment of CMVE with IL-1beta 24 h before adhesion assay. D: addition of TNF-{alpha} (10 ng/ml) to CMVE, MSCs, or both 24 h before adhesion assay increased adhesion of MSCs to CMVE. E: adhesion of MSCs to different cell types with or without pretreatment with TNF-{alpha} (10 ng/ml) for 24 h. AE, aortic endothelium. Values are means ± SE. *P < 0.05 compared with control.

 
In Vivo Adhesion of MSCs

The in vitro experiments indicated that MSCs adhere to CMVE in flow conditions and that adhesion is sensitive to proinflammatory cytokines. As a next step, DiI-labeled MSCs were injected into the left ventricular cavity of anesthetized rats, while the ascending aorta was clamped. In 6 of the 12 rats, MSCs had been pretreated with TNF-{alpha} (10 ng/ml, 24 h). Twenty-four hours after injection, MSCs residing in the myocardium were visualized by fluorescence microscopy. When compared with hearts injected with control MSCs, hearts injected with TNF-{alpha}-treated cells contained three times more MSCs (23 ± 7 vs. 70 ± 19 cells/field, P = 0.046, Fig. 4C). Sections for confocal microscopy were stained with anti-RECA antibody to evaluate spatial relationships between MSCs and cardiac endothelial cells (Fig. 4, A, B, D, and E). Most of the MSCs were observed inside capillaries (Fig. 4D), whereas some of them already crossed the endothelial barrier (Fig. 4E). No MSCs were observed in larger vessels. There were no obvious differences in localization between control MSCs and TNF-treated MSCs (data not shown). MSCs injected 24 h after ischemia (30 min)-reperfusion injury homed abundantly in infarcted tissue (Fig. 4F).


Figure 4
View larger version (79K):
[in this window]
[in a new window]
 
Fig. 4. In vivo homing of MSCs. A and B: fluorescence microscopy mosaic image of left ventricle 24 h after intracavitary injection of 1.5 million control MSCs (A) and TNF-{alpha}-treated MSCs (B). Red, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled MSCs; blue, Hoechst-labeled nuclei; green, rat endothelial cell antigen (RECA)-labeled endothelial cells. C: DiI-labeled MSCs counted in 3 low-magnification fields per rat heart (x40), 24 h after intracavitary injection of 1.5 million MSCs; 6 animals per group. Values are means ± SE. D: 3-dimensional (3-D) projection of a Z-stack reconstruction image of a MSC (red, arrowhead) residing in a capillary. Most MSCs were inside capillaries 24 h after injection due to 3-D reconstruction; red color is partially covered by green color of surrounding capillary. E: 3-D projection of a Z-stack reconstruction image of a MSC (red, arrowhead) outside a capillary, representative for a minor fraction of MSCs that already crossed endothelial barrier 24 h after injection. Red, DiI-labeled MSCs; blue, Hoechst-labeled nuclei; green, RECA-labeled endothelial cells. F: fluorescence microscopy mosaic image of subendocardial myocardium, damaged by ischemia (30 min)-reperfusion injury. Injured myocytes are stained dark green (F-actin staining) and are more loosely organized than intact areas. As evident from the images, there was abundant homing of MSCs (DiI, red) in the infarcted region of the subendocardial infarct. Red, DiI-labeled MSCs; blue, Hoechst-labeled nuclei; green, phalloidin-labeled F-actin.

 
Role of VCAM-1 and ICAM-1

The hyperbolic relation between flow velocity and MSC adhesion to CMVE suggests a role for {alpha}4-integrins (including {alpha}4beta1-integrin = VLA-4, most important ligand of VCAM-1) in mediating cell adhesion (13). Furthermore, adhesion above 0.5 dyn/cm2 argues against involvement of beta2-integrins, which are ligands to ICAM-1 (13). Therefore, monoclonal blocking antibodies against VCAM-1 were added to CMVE 1 h before MSC incubation. VCAM-1 antibody completely abolished the TNF-{alpha}-induced increase of MSC adhesion (n = 6, after stimulation with TNF-{alpha}, from 52 ± 5% to 28 ± 4%, P = 0.013). Monoclonal blocking antibodies against ICAM-1, however, had a slight but nonsignificant effect (n = 6, after stimulation with TNF-{alpha}, from 52 ± 5% to 38 ± 5%, P = 1) (Fig. 5A). Similarly, anti-VCAM-1 antibodies added to MSCs 1 h before adhesion assays inhibited the TNF-{alpha}-induced increase of MSC adhesion (n = 6, after stimulation with TNF-{alpha}, from 66 ± 9% to 5 ± 1%, P = 0.001) and also reduced adhesion in basal conditions (n = 6, from 24 ± 4% in control to 5 ± 1%, P = 0.006). Again, anti-ICAM-1 antibodies added to MSCs before adhesion assays had no effect on MSC adhesion (Fig. 5B).


Figure 5
View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5. Blocking adhesion with antibodies. A: CMVE were treated with TNF-{alpha} (10 ng/ml) 24 h before the adhesion assay and with monoclonal antibodies (Ab) against VCAM-1 and ICAM-1 (10 µg/ml) 1 h before adhesion assay. B: MSCs were treated with TNF-{alpha} (10 ng/ml) 24 h before the adhesion assay and incubated with monoclonal antibodies against VCAM-1 and ICAM-1 (10 µg/ml) 1 h before adhesion. Values are means ± SE; *P < 0.05 compared with control, §P < 0.05 compared with TNF-{alpha}-treated control.

 
Consistent with these observations, treatment of CMVE with TNF-{alpha} (10 ng/ml) or IL-1beta (10 ng/ml) robustly induced VCAM-1 mRNA expression levels by, respectively, 88 ± 31-fold (n = 4, P = 0.005) or 60 ± 15-fold (n = 4, P = 0.002) (Fig. 6). Similarly, treatment of MSCs with TNF-{alpha} or IL-1beta resulted in a 41 ± 8-fold (n = 4, P < 0.001) or 31 ± 8-fold (n = 4, P < 0.001) induction of VCAM-1 mRNA expression, respectively. When compared with VCAM-1 expression, mRNA levels of VLA-4, the principal VCAM-1 ligand, were not affected by TNF-{alpha}, either in CMVE or in MSCs (data not shown). Of note, basal expression levels of VLA-4 mRNA were similar in CMVE and MSCs. However, basal expression levels of VCAM-1 mRNA was 114 times (95% confidence interval from 38 to 341 times) higher in CMVE than in MSCs.


Figure 6
View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6. Expression of VCAM-1. Expression levels of VCAM-1 mRNA compared with control in CMVE and MSCs measured with real-time PCR and normalized to GAPDH mRNA expression levels. TNF-{alpha} (10 ng/ml) and IL-1beta (10 ng/ml) were added to CMVE and MSCs for 7 h. *P < 0.05 compared with control CMVE, §P < 0.05 compared with control MSCs.

 

    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Until recently, it was generally accepted that the damaged heart did not regenerate. Meanwhile, several investigators have demonstrated that bone marrow stem cells, including MSCs, are capable of transdifferentiating into cardiomyocytes in vivo (29) and in vitro (18). From these observations, it has been hypothesized that circulating MSCs (14) could serve as a source for regeneration of damaged myocardial cells. Moreover, MSCs have been shown to increase neovascularization (24) and to mediate paracrine effects (9, 28). An important first step required for cardiac regeneration by circulating stem cells involves adhesion of these cells to cardiac microvascular endothelium (CMVE). In the present study, we show, for the first time, that there is a biological and molecular basis for an intercellular interaction between MSCs and CMVE and that both cell types can be activated for mutual interaction by certain cytokines.

Inflammatory cytokines (TNF-{alpha} and IL-1beta) enhanced adhesion of MSCs to CMVE in conditions of no flow and in conditions of flow in vitro and the intact animal. These cytokines are released in myocarditis, during acute coronary syndromes, and in chronic heart failure (7, 19). The present observation that these proinflammatory cytokines promote homing of stem cells in the heart may suggest that these cytokines have a positive effect on cardiac regeneration. Albeit speculative, the potential beneficial effect of TNF-{alpha} on cardiac cellular homeostasis could be an explanation for the disappointing results of recent clinical trials with TNF-{alpha} inhibitors in heart failure (19). Activation of MSC adhesion does not seem to be a common feature of cytokines in general because other cytokines, including IL-6, IL-3, SCF, and SDF-1, had no effect on MSC adhesion to CMVE.

Our experiments showed that adhesion of MSCs to CMVE was dependent on the flow velocity of the superfusing fluid and rapidly decreased when flow velocities increased. This relation followed a hyperbolic curve, which bends at levels of shear stress between 1 and 2 dyn/cm2. Importantly, this range corresponds to the level of stress observed in veins and capillaries. Whether adhesion of MSCs remains still significant at arterial shear stress levels (usually assumed between 6 and 40 dyn/cm2) remains to be determined (13). Interestingly, a hyperbolic relation between adhesion and shear stress suggests a role for {alpha}4-integrins in mediating cell adhesion (13) and contrasts with the adhesion-shear stress relationship mediated by beta2-integrins, which cannot support adhesion when wall shear stress is >0.5 dyn/cm2.

Consistently, VCAM-1, which interacts with {alpha}4-integrins, appeared to be the dominant adhesion molecule in the cytokine-induced adhesion of MSCs to CMVE. Interestingly, VCAM-1 was inducible in both CMVE and MSCs. Similarly, the {alpha}4beta1-integrin VLA-4, the most important ligand of VCAM-1, was also expressed in both MSCs and CMVE. VLA-4 expression, however, was not inducible by TNF-{alpha} and IL-1beta, indicating that MSC adhesion to CMVE is likely controlled by variations in VCAM-1 expression levels. Interestingly, in contrast to neutrophil adhesion to endothelium (17, 27), adhesion of MSCs to CMVE was less dependent on CD18-ICAM-1 interactions.

A model for the interactions between stem cells and cardiac endothelium is depicted in Fig. 7. Regeneration of cardiac tissue by adult bone marrow stem cells will require mobilization of stem cells on cardiac insult. SDF-1 is cited frequently as a candidate to attract stem cells to injured heart (10). Once MSCs circulate in the blood stream, adhesion to endothelial cells at the site of interest is the first step in homing of those stem cells to heart. Our in vitro results show that inflammatory cytokines can activate both endothelial cells and MSCs. It has been shown previously that cardiac damage augments endothelial VCAM-1 expression in vivo (16). Our in vivo data show that pretreatment of MSCs with TNF-{alpha} increases homing of those cells to the heart and that MSCs home in infarcted tissue, which is consistent with previous reports (3, 30). Whether circulating MSCs express VCAM-1 in conditions of myocardial infarction for homing purposes remains to be elucidated.


Figure 7
View larger version (20K):
[in this window]
[in a new window]
 
Fig. 7. Model of MSC-CMVE interactions. On cardiac insult, inflammatory cytokines play a crucial role in signaling to cardiac endothelial cells and possibly to MSCs. Both cell types express more VCAM-1 after stimulation with these cytokines, leading eventually to increased adhesion of MSCs in capillaries. AMI, acute myocardial infarction.

 
In our in vivo model, 1.5 million stem cells are injected in the vasculature in a few seconds, which might be therapeutically relevant but obviously is far from the physiological situation. The number of circulating stem cells in the intact animal after myocardial damage will only be a very small fraction of the number of cells we injected and only becomes biologically significant if sustained over a longer period.

Besides interacting with CMVE, MSCs also adhered to AE, indicating that interaction of MSCs with endothelial cells may be a general endothelial feature. Adhesion of MSCs to vascular endothelial cells can be of importance for repair of arterial wall (2, 6). To what extent, however, this process may be blunted by high shear forces in the arterial vasculature remains to be determined. Furthermore, on the basis of the present study, homing of stem cells will depend on the number of adhesion molecules expressed by the endothelium. Interestingly, a recent report indicates that microvascular endothelial cells have a much higher constitutive VCAM-1 expression in the heart compared with the lungs (15).

In summary, we demonstrated for the first time that MSCs adhere to CMVE and that adherence properties of both cell types can be modified by proinflammatory cytokines (TNF-{alpha} and IL-1beta). Cytokine-induced adhesion is, at least partly, mediated by the VCAM-1-VLA-4 pathway, with both components of this pathway expressed on both CMVE and MSCs.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
V. F. M. Segers was supported by a grant as a Research Assistant of the Research Foundation-Flanders (FWO-Vlaanderen). This study was supported by the Belgian Science Policy (Project No. IAP-P5/02), by the Research Foundation-Flanders (Project No. G.0131.05), and by a "Bekales research grant" (Liechtenstein) in the field of cardiology.


    FOOTNOTES
 

Address for reprint requests and other correspondence: G. De Keulenaer, Laboratory of Physiology, Univ. of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium (e-mail: gilles.dekeulenaer{at}ua.ac.be)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Adamopoulos S, Parissis JT, and Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 3: 517–526, 2001.[CrossRef][ISI][Medline]
  2. Ball SG, Shuttleworth AC, and Kielty CM. Direct cell contact influences bone marrow mesenchymal stem cell fate. Int J Biochem Cell Biol 36: 714–727, 2004.[CrossRef][ISI][Medline]
  3. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, and Leor J. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108: 863–868, 2003.[Abstract/Free Full Text]
  4. Blau HM, Brazelton TR, and Weimann JM. The evolving concept of a stem cell: entity or function? Cell 105: 829–841, 2001.[CrossRef][ISI][Medline]
  5. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 83: 59–115, 2003.[Abstract/Free Full Text]
  6. Davani S, Marandin A, Mersin N, Royer B, Kantelip B, Herve P, Etievent JP, and Kantelip JP. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation 108, Suppl 1: II253–II258, 2003.
  7. Frangogiannis NG, Smith CW, and Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 53: 31–47, 2002.[Abstract/Free Full Text]
  8. Fransen P, Lamberts RR, Hendrickx J, and De Keulenaer GW. Endocardial endothelium modulates subendocardial pHi of rabbit papillary muscles: role of transendothelial HCO3 transport. Cardiovasc Res 63: 700–708, 2004.[Abstract/Free Full Text]
  9. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, and Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 11: 367–368, 2005.[CrossRef][ISI][Medline]
  10. Goette A, Jentsch-Ullrich K, Lendeckel U, Rocken C, Agbaria M, Auricchio A, Mohren M, Franke A, and Klein HU. Effect of atrial fibrillation on hematopoietic progenitor cells: a novel pathophysiological role of the atrial natriuretic peptide? Circulation 108: 2446–2449, 2003.[Abstract/Free Full Text]
  11. Hendrickx J, Doggen K, Weinberg EO, Van Tongelen P, Fransen P, and De Keulenaer GW. Molecular diversity of cardiac endothelial cells in vitro and in vivo. Physiol Genomics 19: 198–206, 2004.[Abstract/Free Full Text]
  12. Imai K, Kobayashi M, Wang J, Ohiro Y, Hamada J, Cho Y, Imamura M, Musashi M, Kondo T, Hosokawa M, and Asaka M. Selective transendothelial migration of hematopoietic progenitor cells: a role in homing of progenitor cells. Blood 93: 149–156, 1999.[Abstract/Free Full Text]
  13. Konstantopoulos K, Kukreti S, and McIntire LV. Biomechanics of cell interactions in shear fields. Adv Drug Delivery Res 33: 141–164, 1998.[CrossRef][ISI][Medline]
  14. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, and Robey PG. Circulating skeletal stem cells. J Cell Biol 153: 1133–1140, 2001.[Abstract/Free Full Text]
  15. Lim YC, Garcia-Cardena G, Allport JR, Zervoglos M, Connolly AJ, Gimbrone MA Jr, and Luscinskas FW. Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment. Am J Pathol 162: 1591–1601, 2003.[Abstract/Free Full Text]
  16. Lu L, Chen SS, Zhang JQ, Ramires FJ, and Sun Y. Activation of nuclear factor-{kappa}B and its proinflammatory mediator cascade in the infarcted rat heart. Biochem Biophys Res Commun 321: 879–885, 2004.[CrossRef][ISI][Medline]
  17. Ma XL, Lefer DJ, Lefer AM, and Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 86: 937–946, 1992.[Abstract/Free Full Text]
  18. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, and Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103: 697–705, 1999.[ISI][Medline]
  19. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91: 988–998, 2002.[Abstract/Free Full Text]
  20. Mantovani A, Bussolino F, and Dejana E. Cytokine regulation of endothelial cell function. FASEB J 6: 2591–2599, 1992.[Abstract]
  21. Netelenbos T, van den BJ, Kessler FL, Zweegman S, Merle PA, van Oostveen JW, Zwaginga JJ, Huijgens PC, and Drager AM. Proteoglycans on bone marrow endothelial cells bind and present SDF-1 towards hematopoietic progenitor cells. Leukemia 17: 175–184, 2003.[CrossRef][ISI][Medline]
  22. Pittenger MF and Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95: 9–20, 2004.[Abstract/Free Full Text]
  23. Rombouts WJ and Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 17: 160–170, 2003.[CrossRef][ISI][Medline]
  24. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, and Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111: 150–156, 2005.[Abstract/Free Full Text]
  25. Solanilla A, Grosset C, Duchez P, Legembre P, Pitard V, Dupouy M, Belloc F, Viallard JF, Reiffers J, Boiron JM, Coulombel L, and Ripoche J. Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. Br J Haematol 120: 782–786, 2003.[CrossRef][ISI][Medline]
  26. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76: 301–314, 1994.[CrossRef][ISI][Medline]
  27. Tanaka M, Brooks SE, Richard VJ, FitzHarris GP, Stoler RC, Jennings RB, Arfors KE, and Reimer KA. Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after ischemia and reperfusion in dogs. Circulation 87: 526–535, 1993.[Abstract/Free Full Text]
  28. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, and Phillips MI. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept 117: 3–10, 2004.[CrossRef][ISI][Medline]
  29. Wang JS, Shum-Tim D, Galipeau J, Chedrawy E, Eliopoulos N, and Chiu RC. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg 120: 999–1005, 2000.[Abstract/Free Full Text]
  30. Wu GD, Nolta JA, Jin YS, Barr ML, Yu H, Starnes VA, and Cramer DV. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 75: 679–685, 2003.[ISI][Medline]
  31. Yong KL, Watts M, Shaun TN, Sullivan A, Ings S, and Linch DC. Transmigration of CD34+ cells across specialized and nonspecialized endothelium requires prior activation by growth factors and is mediated by PECAM-1 (CD31). Blood 91: 1196–1205, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Stem CellsHome page
L. da Silva Meirelles, A. I. Caplan, and N. B. Nardi
In Search of the In Vivo Identity of Mesenchymal Stem Cells
Stem Cells, September 1, 2008; 26(9): 2287 - 2299.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. Li, D. H. Kim, P. L. Tsenovoy, S. J. Peterson, R. Rezzani, L. F. Rodella, W. S. Aronow, S. Ikehara, and N. G. Abraham
Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance
Diabetes, June 1, 2008; 57(6): 1526 - 1535.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
N. Bonaros, R. Rauf, E. Werner, B. Schlechta, E. Rohde, A. Kocher, J. Bonatti, and G. Laufer
Neoangiogenesis after combined transplantation of skeletal myoblasts and angiopoietic progenitors leads to increased cell engraftment and lower apoptosis rates in ischemic heart failure
Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 249 - 255.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
G. Chamberlain, J. Fox, B. Ashton, and J. Middleton
Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing
Stem Cells, November 1, 2007; 25(11): 2739 - 2749.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. J. Bivalacqua, W. Deng, M. Kendirci, M. F. Usta, C. Robinson, B. K. Taylor, S. N. Murthy, H. C. Champion, W. J. G. Hellstrom, and P. J. Kadowitz
Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1278 - H1290.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Ruster, S. Gottig, R. J. Ludwig, R. Bistrian, S. Muller, E. Seifried, J. Gille, and R. Henschler
Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells
Blood, December 1, 2006; 108(12): 3938 - 3944.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Wang, P. R. Crisostomo, C. Herring, K. K. Meldrum, and D. R. Meldrum
Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism
Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2006; 291(4): R880 - R884.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/4/H1370    most recent
00523.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Segers, V. F. M.
Right arrow Articles by De Keulenaer, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Segers, V. F. M.
Right arrow Articles by De Keulenaer, G. W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.